New Scoring Model Predicts Lung Disease Mortality
Researchers present interim findings on a tool designed to estimate one-year mortality in patients with complex lung conditions.
Updated on Oct. 26, 2026 in Asthma
Live Poll
Should healthcare systems prioritize earlier diagnostic screening for patients with chronic lung conditions?
Scientists have introduced the PVD-B65 scoring model to predict mortality risks for patients suffering from both interstitial lung disease and pulmonary hypertension. The interim findings from the PHINDER study offer a new approach to stratifying patient risk and informing clinical treatment plans.
Why it matters
Developing precise diagnostic scores is essential for identifying high-risk patients who require more aggressive intervention. This tool aims to improve outcomes for individuals managing complex conditions where pulmonary fibrosis and vascular pressure significantly impact survival rates.
The PHINDER study utilized a point-based scoring system ranging from 0 to 14, incorporating B-type natriuretic peptide levels and 6-minute walk test results. Among 119 participants, 12% of those with idiopathic pulmonary fibrosis were classified as high-risk.
The players
American College of Chest Physicians
This is a professional medical association that hosts the annual CHEST meeting to disseminate new research in pulmonary and critical care medicine.
Temple University
This is a public research university in Philadelphia that provided the research team responsible for the study.
Tufts Medical Center
This is a teaching hospital in Boston that contributed specialist clinical expertise to the research effort.
The details
The PVD-B65 model assesses risk factors including pulmonary fibrosis, 6-minute walk test performance, and pulmonary vascular resistance. By categorizing patients into low, intermediate, and high-risk groups, clinicians hope to better manage pulmonary hypertension in those with existing interstitial lung disease.
Timeline
October 2026: PHINDER study interim data presented at CHEST meeting.
2025: FDA approved treprostinil for patients with PH-ILD.
The Big Picture
This study builds upon the regulatory progress made by the 2025 FDA approval of treprostinil for PH-ILD by providing a diagnostic score to better target such therapies to patients most in need.
This diagnostic tool could lead to more personalized treatment pathways for patients dealing with the intersection of lung disease and high blood pressure. By identifying high-risk patients earlier, doctors may be able to adjust medical routines and initiate specialized therapies sooner.
The takeaway
Predictive scoring models are increasingly vital for managing diseases with complex, overlapping symptoms like pulmonary hypertension. Patients should discuss their specific risk factors and diagnostic tests with their pulmonologist to ensure the most current evidence-based care is being applied.
Further reading
For more on managing chronic respiratory conditions, visit the Asthma section.
Source note: This article includes information reported by Medscape.
Live Poll
Should healthcare systems prioritize earlier diagnostic screening for patients with chronic lung conditions?
